| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8411274 | Drug Discovery Today: Technologies | 2015 | 6 Pages |
Abstract
A very large corpus of biological assay screening results exist in the public domain. The ability to compare and analyze this data is hampered due to missing details and lack of a commonly used terminology to describe assay protocols and assay endpoints. Minimum reporting guidelines exist that, if followed, would greatly enhance the utility of biological assay screening data so it may be independently reproduced, readily integrated, effectively compared, and rapidly analyzed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Evan Bolton,